Financial Results Announcement - Medtronic plc will report its financial results for the second quarter of fiscal year 2025 on November 19, 2024, with a news release at approximately 5:45 a.m. CST [1] - The second quarter ended on October 25, 2024, and the summary financial information will be included in the news release [1] Webcast Details - A video webcast to discuss the second quarter results will be hosted by Medtronic at 7:00 a.m. CST on November 19, 2024 [2] - The webcast can be accessed through Medtronic's investor relations website, and a replay and transcript will be available within 24 hours of the broadcast [2] Future Reporting Schedule - Medtronic plans to report its third quarter results on February 18, 2025, and the fourth quarter results on May 21, 2025 [3] Company Overview - Medtronic is a leading global healthcare technology company headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [4] - The company focuses on addressing challenging health problems and offers technologies that treat 70 health conditions, including cardiac devices, surgical robotics, and patient monitoring systems [4] - Medtronic's mission is to alleviate pain, restore health, and extend life, delivering innovative technologies that transform lives [4]

Healthcare Industry Overview - Defensive industries like healthcare are attractive to income investors due to their resilience during economic downturns, as medical needs are non-optional [2] - The healthcare sector is home to many excellent dividend stocks, including Merck and Medtronic [2] Merck (MRK) - Merck's shares are down by 4% this year, partly due to investor concerns about potential competition for its key cancer drug, Keytruda [3] - Keytruda, Merck's largest growth driver, faces competition from Summit Therapeutics' ivonescimab in non-small cell lung cancer (NSCLC) [3] - Keytruda will lose patent exclusivity in the U.S. in 2028, but its revenue is expected to grow until then due to FDA approvals across multiple indications [4] - Merck is developing a subcutaneous version of Keytruda, which will retain exclusivity post-2028 [4] - The company has a robust pipeline with several dozen programs and has expanded through acquisitions, such as Acceleron Pharma, leading to the approval of Winrevair for pulmonary arterial hypertension [5] - Merck collaborates with smaller companies, including Moderna, on a personalized cancer vaccine [6] - Merck's dividend payouts have increased by 71% over the past decade, with a forward yield of 2.96%, higher than the S&P 500 average of 1.32% [6] - Merck remains a reliable income stock with a strong dividend record [7] Medtronic (MDT) - Medtronic has increased its dividend payouts for 47 consecutive years, showcasing its strong business model [8] - The company operates in over 100 countries and offers a wide range of medical devices across several categories [8] - Medtronic's diabetes care segment, particularly its MiniMed 780G insulin pump with meal-detection technology, is a significant growth driver [9] - The company is developing the Hugo robotic-assisted surgery system, which could benefit from the growing demand for minimally invasive surgeries due to the aging population [9][10] - Medtronic has faced challenges in revenue growth recently but is expected to recover and continue increasing its dividend payouts in the long term [11]

Medtronic (MDT) closed the latest trading day at $90.07, indicating a +0.92% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. Meanwhile, the Dow experienced a rise of 0.69%, and the technology-dominated Nasdaq saw an increase of 0.8%.The medical device company's stock has climbed by 1.69% in the past month, exceeding the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97%.Analysts and investors alike will be keeping a close eye on ...

Medtronic (MDT) closed the latest trading day at $90.60, indicating a +0.01% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, the Dow gained 0.65%, and the Nasdaq, a tech-heavy index, added 0.26%.Shares of the medical device company witnessed a gain of 1.42% over the previous month, beating the performance of the Medical sector with its loss of 4.14% and underperforming the S&P 500's gain of 2%.Investors will be eagerly watching for th ...

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial GALWAY, Ireland and WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity™ Spyral renal denervation (RDN) system had significantly greater reduct ...

With this approval, Medtronic is now the first and only company with two PFA technologies available for patients with Afib. The PulseSelect™ Pulsed Field Ablation System, which was FDA approved in December 2023, offers physicians a safe, single-shot solution for pulmonary vein isolation (PVI) while the Affera Sphere-9 catheter enables physician treatment flexibility with its wide area focal design and 9mm lattice tip that can used with an 8.5Fr sheath. "The significance of this innovative technology should ...

October 24, 2024 Both companies also join the newly established World Stroke Organization Advocacy Coalition Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke care is crucial to saving lives and reducing long-term disability. As leaders in stroke diagnosis and treatment, the two organizations are advocat ...

Medtronic (MDT) closed at $91.12 in the latest trading session, marking a +0.1% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.05% for the day. Elsewhere, the Dow lost 0.02%, while the tech-heavy Nasdaq added 0.18%. Prior to today's trading, shares of the medical device company had gained 1.3% over the past month. This has outpaced the Medical sector's loss of 4.16% and lagged the S&P 500's gain of 2.76% in that time. Investors will be eagerly watching for the performa ...

Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revis ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios. Navigating this market can be a tricky endeavor. For one thing, there is plenty of interest rate uncertainty given the Fed's delicate balancing act of contr ...